Overview
CJC-1295 (DAC) is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) that incorporates a Drug Affinity Complex (DAC) designed to bind circulating serum proteins. This modification significantly prolongs peptide persistence in preclinical research models, allowing sustained receptor engagement over extended timeframes.
This compound is supplied strictly for laboratory and investigational research purposes.
Compound Breakdown
The Drug Affinity Complex (DAC) component enables CJC-1295 to reversibly associate with albumin, reducing rapid clearance observed with non-modified GHRH analogs. In laboratory research settings, this allows investigation into:
Prolonged GHRH receptor stimulation
Sustained growth hormone signaling dynamics
Temporal signaling effects associated with extended peptide exposure
Comparative duration-dependent pathway activation
This extended activity profile distinguishes CJC-1295 (DAC) from shorter-acting GHRH analogs.
Research Context
Research investigations involving CJC-1295 (DAC) commonly explore:
Long-duration growth hormone signaling models
Endocrine rhythm and signaling persistence studies
Comparative research versus non-DAC GHRH analogs
Experimental frameworks requiring reduced dosing frequency
These studies are limited to controlled laboratory environments and do not imply clinical or therapeutic outcomes.
Related Categories
CJC-1295 (DAC) is frequently compared with CJC-1295 (No DAC) Peptide and is also incorporated into combination research formulations such as the GH Release Bundle.
